Endocrine therapy, the standard of care for ER+ breast cancer, refers to those interventions that suppress estrogen production as well as strategies that target ERα directly and comprises three main categories: selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs). Here, ESR1 is linked to breast cancer.